Fortrea
FTRE · NYSE · Healthcare · United States
Financials at a glance
Source: SEC XBRLAnnual
Quarterly · last 8
Revenue (FY2025)
$2.7B
Net margin
-36.2%
ROE
-175.0%
Revenue CAGR (2y)
-2.1%
EPS (FY2025)
-10.81
Net profit (FY2025)
$-986.2M
Ask MarketChacha about FTRE
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Sep 2, 2026
Fortrea shares rose after the company announced a $45 million all-cash acquisition of Worldwide Clinical Trials' Early Phase Services division, adding bioanalytical labs, a clinical pharmacology unit, and related Texas facilities to strengthen its Phase I-IV capabilities.
- Sep 1, 2026
Fortrea shares fell amid recent selling pressure, including a Bank of America stake trim reported today and multiple insider sales plus an analyst downgrade in late August; no new company-specific catalyst or filing was identified for the session.
- Aug 4, 2026
Fortrea shares declined following an Aug 3 announcement of an insider's planned Rule 144 sale of 9,700 shares, with the drop continuing from the prior session after the company's July 29 earnings release that included raised full-year guidance.
- Jul 23, 2026
No specific company catalyst identified for the gain; the stock rose ahead of its scheduled Q2 earnings release on July 29 with no new filings or announcements today.
· confidence: low - Jul 22, 2026
No specific company catalyst or news event identified for the gain; FTRE moved with the broader market or sector amid upcoming Q2 earnings scheduled for July 29.
· confidence: low
Daily moves with the verified reason behind them. Education only — not investment advice.
On MarketChacha
Posts about FTREFinancials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $2.7B | $-986.2M | -10.81 | -36.2% | -175.0% |
| FY2024 | $2.7B | $-328.5M | -3.67 | -12.2% | -24.1% |
| FY2023 | $2.8B | $-25.2M | -0.29 | -0.9% | -1.5% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q2 | $678.2M | $-13.2M | -0.14 | -1.9% |
| 2026Q1 | $636.5M | $-23.6M | -0.25 | -3.7% |
| 2025Q3 | $701.3M | $-15.9M | -0.17 | -2.3% |
| 2025Q2 | $710.3M | $-374.9M | -4.14 | -52.8% |
| 2025Q1 | $651.3M | $-562.9M | -6.25 | -86.4% |
| 2024Q3 | $674.9M | $-27.9M | -0.31 | -4.1% |
| 2024Q2 | $662.4M | $-138.4M | -1.55 | -20.9% |
| 2024Q1 | $662.1M | $-101.0M | -1.13 | -15.3% |
| 2023Q3 | $713.8M | $-14.0M | -0.16 | -2.0% |
| 2023Q2 | $725.1M | $30.8M | 0.35 | 4.2% |
| 2023Q1 | $693.9M | $12.5M | 0.14 | 1.8% |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC7/29/2026
- SEC7/29/2026material
- SEC7/14/2026material
- SEC6/26/2026material
- SEC6/12/2026material
- SEC5/5/2026material
- SEC5/5/2026
- SEC2/26/2026material
- SEC2/26/2026
2025
- SEC11/20/2025material
- SEC11/5/2025material
- SEC11/5/2025
- SEC9/22/2025material
- SEC8/27/2025material
- SEC8/6/2025material
- SEC8/6/2025
In the news
- Wellington Management Group LLP Invests $41.49 Million in Fortrea Holdings Inc. $FTREMarketBeat · 9/4/2026
- Fortrea Leverages Early Phase Strengths to Accelerate Market ExpansionBenzinga · 9/2/2026
- Bank of America Corp DE Trims Stake in Fortrea Holdings Inc. $FTREMarketBeat · 9/1/2026
- Fortrea (NASDAQ:FTRE) Downgraded by Wall Street Zen to HoldMarketBeat · 8/29/2026
- Fortrea COO Mark Morais sells $88,985 in shares after RSU vestingInvesting.com · 8/27/2026
- Royal Bank of Canada Has $736,000 Stake in Fortrea Holdings Inc. $FTREMarketBeat · 8/24/2026
- Fortrea Holdings COO Mark Morais sells $88,985 in company stock. By Investing.comInvesting.com India · 8/20/2026
- Fortrea Holdings (FTRE) COO has 11,313 RSUs vestStock Titan · 8/19/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.